---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-26-004020"
form_type: "8-K"
ticker: "ASPI"
cik: "0001921865"
company_name: "ASP Isotopes Inc."
filed_at: "2026-06-25T21:24:49+00:00"
generated_at: "2026-06-25T21:26:22.690695+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ASPI subsidiary Noble to merge into ENDRA Life Sciences with $50M investment; renamed Noble Africa Inc.

## Summary
- Merger: Noble (ASPI subsidiary) merges into ENDRA; each Noble unit converts to one share of Class A or Class B common stock.
- Noble Investment: ~$50M gross proceeds from 4.59M Class A units at $6.57/unit to institutional investors and 3.05M Class B units to ASPI.
- ASPI contributes its Renergen subsidiary to Noble for 55.5M Class B units, entitling ASPI to 10 votes per share in ENDRA.
- Closing conditions include ENDRA stockholder approval, SEC effectiveness, Nasdaq listing, OPIC consent, and ENDRA having ≥$3.8M cash.
- Expected closing by Dec 24, 2026; ASPI directors (Mann, Ryan, Ainscow, Moore) subscribe for ~$750K of Noble Class A units.

## SEC filing metadata
- accession: 0001477932-26-004020
- form_type: 8-K
- ticker: ASPI
- cik: 0001921865
- company_name: ASP Isotopes Inc.
- filed_at: 2026-06-25T21:24:49+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1921865/000147793226004020/0001477932-26-004020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1921865/000147793226004020/aspi_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-26-004020
- JSON: https://secwatch.observer/filing/0001477932-26-004020.json
- Plain text: https://secwatch.observer/filing/0001477932-26-004020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.